Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment-Reference-Cited by-同舟云学术

Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment

Published:2017-12 Issue:1 Volume:7 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Zarone Mayra Rachele^ORCID,Misso Gabriella^ORCID,Grimaldi Anna,Zappavigna Silvia,Russo Margherita,Amler Evzen,Di Martino Maria Teresa,Amodio Nicola,Tagliaferri Pierosandro,Tassone Pierfrancesco,Caraglia Michele^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-017-18186-0.pdf

Reference51 articles.

1. Amodio, N., D’Aquila, P., Passarino, G., Tassone, P. & Bellizzi, D. Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation. Expert OpinTher Targets. 21(1), 91–101 (2017).

2. Bianch, G. & Munshi, N. C. Blood Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood. 125(20), 3049–3058 (2015).

3. Misso, G. et al. Emerging pathways as individualized therapeutic target of multiple myeloma. Expert Opin. Biol. Ther. 1, S95–109 (2013).

4. Pichiorri, F. et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl AcadSci USA 105(35), 12885–90 (2008).

5. Rossi, M. et al. From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario. Curr Drug Targets. 14(10), 1144–9 (2013).

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The NOTCH1 and miR-34a signaling network is affected by TP53 alterations in CLL;Leukemia & Lymphoma;2024-08-19

2. Targeted Delivery Strategies for Multiple Myeloma and Their Adverse Drug Reactions;Pharmaceuticals;2024-06-25

3. miR‐34a promotes the immunosuppressive function of multiple myeloma‐associated macrophages by dampening the TLR‐9 signaling;Cancer Medicine;2024-06

4. Exosomal miRNAs in the Tumor Microenvironment of Multiple Myeloma;Cells;2023-03-28

5. Empagliflozin Improves the MicroRNA Signature of Endothelial Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Diabetes;Journal of Pharmacology and Experimental Therapeutics;2022-07-25